Biosergen AB announced that it has appointed Tine Kold Olesen as Chief Operating Officer. Tine Kold Olesen (MSc, MBA, PhD) has an impressive resume in international drug development. Tine Kold Olesen started her career in the clinical research field in international pharmaceutical companies Novo Nordisk, Glaxo-Welcome and Orion Pharma. From 2001 to 2020 she held positions of ever increasing responsibility in Ferring Pharmaceuticals, ending with her appointment to Senior Director, Global Project and Portfolio Management in Ferring Inc., USA where she managed Ferring's entire Oncology/Urology portfolio in the United States. She will join Biosergen on October 1, 2021.